Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Journey Medical Corp is focused on identifying, acquiring, developing and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model. Journey Medical Corp is focused on identifying, acquiring, developing and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model.
U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of...
SCOTTSDALE, Ariz., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling...
Poster Presented on Dermal and Systemic Pharmacokinetics of Oral DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) versus Oral Doxycycline 40 mg Capsules (Oracea®) in Healthy...
SCOTTSDALE, Ariz., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...
SCOTTSDALE, Ariz., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...
SCOTTSDALE, Ariz., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily...
PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.49 | 9.6837944664 | 5.06 | 5.88 | 5.0201 | 101074 | 5.43660022 | CS |
| 4 | -0.465 | -7.73067331671 | 6.015 | 6.335 | 5 | 146378 | 5.49714193 | CS |
| 12 | 0.64 | 13.0346232179 | 4.91 | 6.705 | 4.51 | 92674 | 5.58711378 | CS |
| 26 | 1.86 | 50.406504065 | 3.69 | 6.705 | 3.5 | 85159 | 5.33516177 | CS |
| 52 | 1.05 | 23.3333333333 | 4.5 | 8.11 | 2.85 | 155559 | 5.17014068 | CS |
| 156 | -2.65 | -32.3170731707 | 8.2 | 8.6 | 1.02 | 91119 | 4.24704358 | CS |
| 260 | -3.3 | -37.2881355932 | 8.85 | 25.99 | 1.02 | 194199 | 12.78139998 | CS |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
